HPV-derived peptide presented by major histocompatibility complex class I

HPV-derived peptide presented by major histocompatibility complex class I refers to an antigenic fragment from HPV viral proteins (typically E6, E7, L1, or L2) processed within an infected or transformed cell, loaded into the binding cleft of MHC-I molecules (such as HLA-A*02:01), and displayed on the cell surface for recognition by the immune system. CD8+ T lymphocytes scan these complexes and initiate an immune response by destroying HPV-infected or malignant cells presenting the foreign peptide. Many therapeutic HPV vaccines aim to induce or enhance this antigen presentation by designing optimized, immunogenic HPV peptides that bind effectively to relevant MHC-I alleles. The peptide–MHC-I complex itself is at the core of therapeutic strategies targeting HPV-driven cancers; it is not an enzyme or receptor but an immunologically critical complex that determines CTL-based recognition and elimination of disease cells.

Other names

HPV antigenic peptide-MHC-I complexHPV epitope-MHC-I complexHPV peptide-HLA class I complex

Presentation of HPV-derived peptide by MHC-I leads to recognition and killing of infected or transformed cells by CD8+ T cells Vaccine-induced expansion of peptide-specific cytotoxic T cells